Brind.

AptarGroup's revenue growth is being compared against the average performance of the US packaging industry.

2 reports, 2 independent Updated Aug 2
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

AptarGroup's revenue growth is being compared against the average performance of the US packaging industry.

Who's involved

What this event is mainly about
Aptar (France )

How it developed

Newest first. Tap a step to see who reported it.
  1. AptarGroup's revenue growth is compared to the US packaging industry average.1 source
  2. Aptar is strengthening its support for early-stage drug development through an acquisition involving MOD3 Pharma.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.AptarGroup Second Quarter 2025 Earnings: EPS Beats Expectations Revenue: US$966.0m (up 6.1% from 2Q 2024). Net income: US$111.7m (up 24% from 2Q 2024). Profit margin: 12% (up from 9.9% in 2Q 2024). T
  • Clinical Trials ArenaAptar acquires Mod3 Pharma’s trial materials manufacturing capabilities Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdin